Myriad Genetics Inc (MYGN)

$3.20 -0.02 (-0.62%)
Market Cap 307.99M
Revenue (ttm) 824.50M
Net Income (ttm) -365.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -44.38%
Debt to Equity Ratio 0.40
Volume 1,279,000
Avg Vol 1,927,494
Day's Range N/A - N/A
Shares Out 95.65M
Stochastic %K 79%
Beta 1.69
Analysts Hold
Price Target $4.29

Company Profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 801 584 3600
Fax: 801 584 3640
Address:
322 North 2200 West, Salt Lake City, United States
Zrahimi
Zrahimi Aug. 18 at 6:51 PM
$MYGN back 2.85 this will rebound a bit
0 · Reply
revoltingtrees
revoltingtrees Aug. 18 at 5:14 PM
$MYGN i smell a buyout. 10k shares avg cost $2.88
1 · Reply
revoltingtrees
revoltingtrees Aug. 18 at 3:47 PM
$MYGN $NVDA
0 · Reply
revoltingtrees
revoltingtrees Aug. 14 at 6:01 PM
$MYGN first time buyer today $3.08. Selling all my $NVDA from 2009, 2012 and 2022. Its been amazing! 🤩 Thank you for the beach house in Miami!
1 · Reply
FeliciaMath
FeliciaMath Aug. 13 at 5:05 PM
$MYGN sold at 3.17. made $52 /3%
0 · Reply
Estimize
Estimize Aug. 10 at 1:15 PM
Wall St is expecting -0.07 EPS for $MYGN Q1 [Reporting 10/27 AMC] http://www.estimize.com/intro/mygn?chart=historical&metric_name=eps&utm_c
0 · Reply
GoCoogs
GoCoogs Aug. 4 at 6:47 PM
$MYGN Rebound rally in motion. Got in at 2.95.
0 · Reply
FeliciaMath
FeliciaMath Aug. 4 at 4:48 PM
bought $MYGN at 3.09
0 · Reply
theBigDollarski
theBigDollarski Aug. 3 at 7:38 PM
$MYGN this company needs to get bought out to a firm that can properly market a product and run a company. This management is horrible.
0 · Reply
AnalyticaInvestor
AnalyticaInvestor Aug. 3 at 10:15 AM
Good morning, investors. Hyperscalers continue accelerating AI infrastructure spending, supporting demand for semiconductor suppliers, networking companies, and specialized hardware providers. Among gainers, $CIGL surged 33% on unusually heavy trading despite no company specific catalyst. On the downside, $MYGN fell 47% after disappointing quarterly results, while $CERS dropped 26% following post earnings selling pressure. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/yields-spike-myriad-down-47
0 · Reply
Latest News on MYGN
Myriad Genetics price target lowered to $3 from $5 at Stephens

2026-08-18T10:35:22.000Z - 4 days ago

Myriad Genetics price target lowered to $3 from $5 at Stephens

MYGN

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

Aug 8, 2026, 2:57 PM EDT - 14 days ago

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

MYGN

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Aug 4, 2026, 11:27 AM EDT - 18 days ago

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

MYGN

Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo

2026-08-03T11:41:18.000Z - 19 days ago

Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo

MYGN

Myriad Genetics price target lowered to $3.20 from $4 at BofA

2026-08-03T11:32:10.000Z - 19 days ago

Myriad Genetics price target lowered to $3.20 from $4 at BofA

MYGN

Myriad Genetics price target lowered to $4 from $6 at TD Cowen

2026-07-31T12:59:45.000Z - 22 days ago

Myriad Genetics price target lowered to $4 from $6 at TD Cowen

MYGN

Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M

2026-07-30T20:45:44.000Z - 23 days ago

Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M

MYGN

Myriad Genetics reports Q2 EPS (25c), consensus (6c)

2026-07-30T20:40:31.000Z - 23 days ago

Myriad Genetics reports Q2 EPS (25c), consensus (6c)

MYGN

Myriad Genetics Earnings Call Transcript: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 23 days ago

Myriad Genetics Earnings Call Transcript: Q2 2026

Myriad Genetics Earnings release: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 23 days ago

Myriad Genetics Earnings release: Q2 2026

Myriad Genetics Slides: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 23 days ago

Myriad Genetics Slides: Q2 2026

Myriad Genetics Quarterly report: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 23 days ago

Myriad Genetics Quarterly report: Q2 2026

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Jul 30, 2026, 4:05 PM EDT - 23 days ago

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

MYGN

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Jul 23, 2026, 9:05 AM EDT - 4 weeks ago

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

MYGN

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Jul 21, 2026, 9:05 AM EDT - 4 weeks ago

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

MYGN

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer

Jul 2, 2026, 9:05 AM EDT - 7 weeks ago

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer

MYGN

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Jun 23, 2026, 9:05 AM EDT - 2 months ago

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

MYGN

Myriad Genetics Transcript: AGM 2026

Jun 4, 2026, 10:00 AM EDT - 2 months ago

Myriad Genetics Transcript: AGM 2026

Myriad Genetics appoints Raj Jampa as chief technology officer

2026-06-02T14:16:51.000Z - 2 months ago

Myriad Genetics appoints Raj Jampa as chief technology officer

MYGN

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

Jun 2, 2026, 9:05 AM EDT - 2 months ago

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

MYGN

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

May 27, 2026, 9:05 AM EDT - 3 months ago

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

MYGN

Myriad Genetics launches Prolaris + AI

2026-05-26T20:39:25.000Z - 3 months ago

Myriad Genetics launches Prolaris + AI

MYGN

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

May 26, 2026, 4:05 PM EDT - 3 months ago

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

MYGN

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

May 15, 2026, 11:00 AM EDT - 3 months ago

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

MYGN

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

May 7, 2026, 4:05 PM EDT - 3 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

MYGN

Myriad Genetics price target lowered to $6 from $7 at TD Cowen

2026-05-07T05:11:29.000Z - 3 months ago

Myriad Genetics price target lowered to $6 from $7 at TD Cowen

MYGN

Myriad Genetics Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Myriad Genetics Earnings Call Transcript: Q1 2026

Myriad Genetics Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Myriad Genetics Earnings release: Q1 2026

Myriad Genetics Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Myriad Genetics Slides: Q1 2026

Myriad Genetics Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Myriad Genetics Quarterly report: Q1 2026

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

May 5, 2026, 4:05 PM EDT - 3 months ago

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

MYGN

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Apr 30, 2026, 9:05 AM EDT - 4 months ago

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

MYGN

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

Apr 28, 2026, 4:05 PM EDT - 4 months ago

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

MYGN

Myriad Genetics to deliver six abstracts at AACR 2026

2026-04-16T13:42:01.000Z - 4 months ago

Myriad Genetics to deliver six abstracts at AACR 2026

MYGN

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

Apr 16, 2026, 9:15 AM EDT - 4 months ago

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

MYGN

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Apr 14, 2026, 9:15 AM EDT - 4 months ago

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

MYGN

Myriad Genetics Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Myriad Genetics Proxy statement: Proxy filing

Myriad Genetics Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Myriad Genetics Proxy statement: Proxy filing

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Apr 9, 2026, 9:15 AM EDT - 4 months ago

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

MYGN

Myriad Genetics announces FDA approval for MyChoice CDx Test

2026-03-17T20:20:19.000Z - 5 months ago

Myriad Genetics announces FDA approval for MyChoice CDx Test

MYGN

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Mar 17, 2026, 4:05 PM EDT - 5 months ago

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

MYGN

Myriad Genetics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:40 PM EDT - 5 months ago

Myriad Genetics Transcript: Leerink Global Healthcare Conference 2026

Myriad Genetics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 3:10 PM EST - 6 months ago

Myriad Genetics Transcript: TD Cowen 46th Annual Health Care Conference

Myriad Genetics files $200M mixed securities shelf

2026-02-24T21:25:02.000Z - 6 months ago

Myriad Genetics files $200M mixed securities shelf

MYGN

Myriad Genetics to present six abstracts at ASCO-GU 2026

2026-02-24T14:07:41.000Z - 6 months ago

Myriad Genetics to present six abstracts at ASCO-GU 2026

MYGN

Myriad Genetics price target lowered to $6 from $8 at UBS

2026-02-24T13:02:15.000Z - 6 months ago

Myriad Genetics price target lowered to $6 from $8 at UBS

MYGN

Myriad Genetics Registration statement: Registration Filing

Feb 24, 2026, 7:00 AM EST - 6 months ago

Myriad Genetics Registration statement: Registration Filing

Myriad Genetics price target lowered to $6 from $6.50 at Wells Fargo

2026-02-24T11:40:44.000Z - 6 months ago

Myriad Genetics price target lowered to $6 from $6.50 at Wells Fargo

MYGN

Myriad Genetics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Earnings Call Transcript: Q4 2025

Myriad Genetics Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Annual report: Q4 2025

Myriad Genetics Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Earnings release: Q4 2025

Myriad Genetics Slides: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Slides: Q4 2025

Myriad Genetics sees Q1 revenue $200M-$203M, consensus $211.19M

2026-02-23T21:28:16.000Z - 6 months ago

Myriad Genetics sees Q1 revenue $200M-$203M, consensus $211.19M

MYGN

Myriad Genetics backs FY26 revenue view $860M-$880M, consensus $868.06M

2026-02-23T21:26:37.000Z - 6 months ago

Myriad Genetics backs FY26 revenue view $860M-$880M, consensus $868.06M

MYGN

Myriad Genetics reports Q4 adjusted EPS 4c, consensus (2c)

2026-02-23T21:15:56.000Z - 6 months ago

Myriad Genetics reports Q4 adjusted EPS 4c, consensus (2c)

MYGN

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Feb 23, 2026, 4:05 PM EST - 6 months ago

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

MYGN

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Feb 19, 2026, 9:15 AM EST - 6 months ago

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

MYGN

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Feb 16, 2026, 4:15 PM EST - 6 months ago

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

MYGN

Myriad Genetics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 7 months ago

Myriad Genetics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Myriad Genetics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 7 months ago

Myriad Genetics Slides: 44th Annual J.P. Morgan Healthcare Conference

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Jan 12, 2026, 8:30 AM EST - 7 months ago

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

MYGN

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:15 PM EST - 8 months ago

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

MYGN

Myriad Genetics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 12:00 PM EST - 9 months ago

Myriad Genetics Transcript: Piper Sandler 37th Annual Healthcare Conference

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Nov 25, 2025, 4:15 PM EST - 9 months ago

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

MYGN

Myriad Genetics Transcript: Wolfe Research Healthcare Conference 2025

Nov 18, 2025, 1:20 PM EST - 9 months ago

Myriad Genetics Transcript: Wolfe Research Healthcare Conference 2025

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Nov 11, 2025, 9:00 AM EST - 10 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

MYGN

Myriad Genetics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Earnings Call Transcript: Q3 2025

Myriad Genetics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Quarterly report: Q3 2025

Myriad Genetics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Earnings release: Q3 2025

Myriad Genetics Slides: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Slides: Q3 2025

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Nov 3, 2025, 4:05 PM EST - 10 months ago

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

MYGN

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Oct 31, 2025, 9:05 AM EDT - 10 months ago

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

MYGN

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Oct 27, 2025, 4:15 PM EDT - 10 months ago

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

MYGN

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

MYGN

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Oct 8, 2025, 5:21 PM EDT - 11 months ago

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

MYGN

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Sep 23, 2025, 8:01 AM EDT - 11 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

MYGN SOPH

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Sep 23, 2025, 8:00 AM EDT - 11 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

MYGN SOPH

Myriad Genetics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 7:45 AM EDT - 1 year ago

Myriad Genetics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

Sep 4, 2025, 7:00 PM EDT - 1 year ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

MYGN

Myriad Genetics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 3:45 PM EDT - 1 year ago

Myriad Genetics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Sep 3, 2025, 4:30 PM EDT - 1 year ago

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

MYGN

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

MYGN

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Aug 13, 2025, 8:00 AM EDT - 1 year ago

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

MYGN

Myriad Genetics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Earnings Call Transcript: Q2 2025

Myriad Genetics Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Quarterly report: Q2 2025

Myriad Genetics Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Earnings release: Q2 2025

Myriad Genetics Slides: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Slides: Q2 2025

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

MYGN

Myriad Genetics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Myriad Genetics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Myriad Genetics Transcript: AGM 2025

Jun 5, 2025, 10:00 AM EDT - 1 year ago

Myriad Genetics Transcript: AGM 2025

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Jun 3, 2025, 9:00 AM EDT - 1 year ago

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

MYGN

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 27, 2025, 4:05 PM EDT - 1 year ago

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

MYGN

Zrahimi
Zrahimi Aug. 18 at 6:51 PM
$MYGN back 2.85 this will rebound a bit
0 · Reply
revoltingtrees
revoltingtrees Aug. 18 at 5:14 PM
$MYGN i smell a buyout. 10k shares avg cost $2.88
1 · Reply
revoltingtrees
revoltingtrees Aug. 18 at 3:47 PM
$MYGN $NVDA
0 · Reply
revoltingtrees
revoltingtrees Aug. 14 at 6:01 PM
$MYGN first time buyer today $3.08. Selling all my $NVDA from 2009, 2012 and 2022. Its been amazing! 🤩 Thank you for the beach house in Miami!
1 · Reply
FeliciaMath
FeliciaMath Aug. 13 at 5:05 PM
$MYGN sold at 3.17. made $52 /3%
0 · Reply
Estimize
Estimize Aug. 10 at 1:15 PM
Wall St is expecting -0.07 EPS for $MYGN Q1 [Reporting 10/27 AMC] http://www.estimize.com/intro/mygn?chart=historical&metric_name=eps&utm_c
0 · Reply
GoCoogs
GoCoogs Aug. 4 at 6:47 PM
$MYGN Rebound rally in motion. Got in at 2.95.
0 · Reply
FeliciaMath
FeliciaMath Aug. 4 at 4:48 PM
bought $MYGN at 3.09
0 · Reply
theBigDollarski
theBigDollarski Aug. 3 at 7:38 PM
$MYGN this company needs to get bought out to a firm that can properly market a product and run a company. This management is horrible.
0 · Reply
AnalyticaInvestor
AnalyticaInvestor Aug. 3 at 10:15 AM
Good morning, investors. Hyperscalers continue accelerating AI infrastructure spending, supporting demand for semiconductor suppliers, networking companies, and specialized hardware providers. Among gainers, $CIGL surged 33% on unusually heavy trading despite no company specific catalyst. On the downside, $MYGN fell 47% after disappointing quarterly results, while $CERS dropped 26% following post earnings selling pressure. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/yields-spike-myriad-down-47
0 · Reply
ShKumaresan
ShKumaresan Aug. 3 at 3:12 AM
$RBLX $HTZ $MYGN Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week? https://stocktwits.com/news-articles/default/equity/why-did-rblx-htz-mygn-stocks-plunge-to-52-week-lows-last-week/cZoRyOBRJ5n
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 3 at 3:12 AM
Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week? $RBLX $HTZ $MYGN https://stocktwits.com/news/equity/markets/why-did-rblx-htz-mygn-stocks-plunge-to-52-week-lows-last-week/cZoRyOBRJ5n
0 · Reply
JustBen47
JustBen47 Aug. 1 at 6:34 PM
$MYGN Not looking good at all
0 · Reply
Ric_1M
Ric_1M Aug. 1 at 2:18 PM
$KPTI $BIOA $NUWE $DFNS $MYGN “Our greatest weakness lies in giving up. The most certain way to succeed is always to try just one more time.” Thomas Edison
0 · Reply
james899
james899 Jul. 31 at 8:50 PM
$MYGN woah what's going on, bankruptcy incoming?
0 · Reply
Gmblr777
Gmblr777 Jul. 31 at 8:45 PM
$MYGN buying
0 · Reply
BenedictBrandon
BenedictBrandon Jul. 31 at 7:35 PM
$MYGN Big buys just came in finally
0 · Reply
F14TOMCATIIAF
F14TOMCATIIAF Jul. 31 at 6:56 PM
$MYGN in
0 · Reply
BenedictBrandon
BenedictBrandon Jul. 31 at 6:35 PM
$MYGN Nobody ever got hurt fallingf out a basement window
0 · Reply
Gmblr777
Gmblr777 Jul. 31 at 6:16 PM
$MYGN buying
0 · Reply
Bebbz88
Bebbz88 Jul. 31 at 6:02 PM
$MYGN I’ll have a gamble here for a quick bounce..
1 · Reply
BenedictBrandon
BenedictBrandon Jul. 31 at 5:39 PM
$MYGN Here comes the dip buyers
0 · Reply